Sarepta Therapeutics Zooms Higher on Early Data Rally Promising
Sarepta Therapeutics surged about 20% after releasing early Phase 1/2 data for SRP-1001 and SRP-1003, signaling poten...
Understand when to opt for long term investing over short term to maximize your investment returns. Discover the key factors influencing your decision.
28,006 articlesSarepta Therapeutics surged about 20% after releasing early Phase 1/2 data for SRP-1001 and SRP-1003, signaling poten...
A lawyer-turned-DJ builds shipping-container sports clubs in refugee camps, blending grant funding with revenue from ...
Perplexity's CEO argues that embracing the risk of idea theft keeps a fast-moving AI startup on its toes. The comment...
A cautionary look at a real-world scam where a fake google support call helped siphon crypto from victim wallets. Lea...
Original Medicare continues to exclude routine dental care, leaving retirees to navigate costly implants, crowns and ...
Apple raises hardware prices by up to 20% amid memory-cost pressures, while Amazon’s AWS sees robust cloud demand. Th...
As AI infrastructure spending persists into July, Teradyne, Ouster, and Vishay Precision Group lead a rally in infras...
A major investment manager disclosed a sizable share disposal in a U.S. utility stock through an SEC filing. The move...
AI infrastructure is booming, but spending fears linger. This piece highlights two credible stock picks that could ri...
When oil prices spike, the market story often shifts. This piece uses prices skyrocketing years history to explore wh...
A biotech ETF posts a 17% gain in the trailing month even as NVIDIA weakens, underscoring a sector rotation that chal...
Tesla is signaling stronger profit margins and robust cash flow, setting up a potential 12% rally in the coming year....